FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Только для исследовательских целей. Полный disclaimer →

Назад в Научную Библиотеку
PubMedReviewЧеловеческие Субъекты

Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition.

Ely Zackery A, Kulstad Zachary J, Gunaydin Gurcan, Addepalli Sudarsana, Verzani Eva K, Casarrubios Marta, Clauser Karl R, Wang Xilin, Lippincott Isabelle E, Louvet Cedric
Science (New York, N.Y.)2025DOI: 10.1126/science.adk3487
cryptic peptidesnoncanonical HLA-I-bound peptides (ncHLAp)pancreatic cancer immunopeptidome

Качественный Балл

6/10

Цитирования

0

Объекты Исследования

Человеческий

Анализ Peptide Contacts

Study Design

Review papers serve a critical role in synthesizing disparate findings into a coherent narrative. For rapidly evolving fields like peptide therapeutics, reviews help researchers and practitioners identify consensus and controversy.

Our Assessment

Quality Assessment: 6/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of cryptic peptides, noncanonical HLA-I-bound peptides (ncHLAp), pancreatic cancer immunopeptidome in meaningful ways. The human-subjects design makes these results particularly relevant for clinical translation.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Decent human data on cryptic peptides, noncanonical HLA-I-bound peptides (ncHLAp), pancreatic cancer immunopeptidome. Not the final word, but a meaningful data point that adds to the weight of evidence.

Ключевые Найденные Результаты

The paper identifies that cryptic peptides are abundant in the pancreatic cancer immunopeptidome, with approximately 30% of noncanonical HLA-I-bound peptides (ncHLAp) being cancer-restricted and shared among patients. These peptides show potential for T cell recognition and tumoricidal activity.

Ограничения

The study is a review paper that synthesizes existing research rather than presenting new primary data, which limits its ability to provide definitive conclusions about the clinical efficacy of targeting cryptic antigens in pancreatic cancer therapy.

Как интерпретировать эту исследовательскую работу

1

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

2

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

3

Reviews are only as good as the studies they include. Check whether the review examined study quality or simply tallied results.

4

Look for discussion of publication bias — studies with negative results are less likely to be published, which can skew review conclusions.

5

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Анализ Peptide Contacts

Highlighting the discovery of abundant cryptic peptides in pancreatic cancer and their potential as targets for T cell recognition, emphasizing the implications for developing new therapeutic strategies.

cryptic peptidesnoncanonical HLA-I-bound peptides (ncHLAp)pancreatic cancer immunopeptidome

Unveiling Hidden Targets: Cryptic Antigens in Pancreatic Cancer

Published: May 16, 2026 | Source: Science (New York, N.Y.) (2025) | Category: cryptic peptides, noncanonical HLA-I-bound peptides (ncHLAp), pancreatic cancer immunopeptidome

Overview

A recent study published in Science reveals that pancreatic cancer cells harbor a significant number of hidden antigens known as cryptic peptides. These findings could pave the way for new therapeutic strategies targeting these specific markers, potentially offering hope to patients with this aggressive form of cancer.

Study Background

Pancreatic cancer is notoriously difficult to treat due to its rapid progression and resistance to conventional therapies. Recent research has focused on identifying unique molecular targets within tumors that can be recognized by the immune system. The study by Ely et al. builds upon previous work suggesting that noncoding regions of the genome, when translated in cancer cells, produce peptides that are presented via human leukocyte antigen class I (HLA-I) molecules. However, the extent to which these cryptic peptides are specific to pancreatic cancer and their potential as therapeutic targets was not fully understood.

What the Research Found

The research team used high-resolution immunopeptidomics to analyze the peptide landscape of pancreatic cancer cells. They discovered that approximately 30% of noncanonical HLA-I-bound peptides (ncHLAp) found in these tumors are unique to pancreatic cancer and shared among different patients. Importantly, these peptides demonstrated robust potential for T cell recognition and could be used to redirect T cells against patient-derived organoids.

What This Means for Peptide Users

While the study is primarily a review of existing research rather than presenting new primary data, it highlights the potential of cryptic antigens as novel targets in pancreatic cancer therapy. For peptide users, this means that future therapeutic strategies might include targeting these specific peptides to enhance immune response against tumors.

Limitations and Caveats

It's important to note that while the findings are promising, they do not provide definitive clinical evidence for the efficacy of targeting cryptic antigens in treating pancreatic cancer. The study synthesizes existing research rather than presenting new primary data, which limits its ability to conclusively prove the therapeutic potential of these peptides.

How This Compares to Previous Research

Previous studies have suggested that noncanonical HLA-I-bound peptides might play a role in immune recognition of cancer cells. However, this review paper provides a more comprehensive analysis and highlights the specific abundance of such peptides in pancreatic cancer, emphasizing their potential as targets for immunotherapy.

Our Analysis

PeptideVault views this study positively, recognizing its contribution to understanding the complex interplay between noncanonical peptides and immune response in pancreatic cancer. While it does not provide conclusive clinical evidence, the findings offer valuable insights that could guide future research and therapeutic development.

Key Takeaways

  • Unique Peptides: Pancreatic cancer cells produce a significant number of unique cryptic peptides.
  • T Cell Recognition: These peptides show potential for T cell recognition and tumoricidal activity.
  • Future Therapies: The findings suggest new avenues for developing targeted therapies against pancreatic cancer.

Original Source

Citation: Ely Zackery A, Kulstad Zachary J, Gunaydin Gurcan et al. (2025). Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition.. Science (New York, N.Y.). DOI: 10.1126/science.adk3487

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Примечание Редактора

Этот анализ был написан командой исследований Peptide Contacts для того, чтобы сделать сложные выводы доступными для сообщества исследований Peptide. Мы призываем читателей проверить исходную статью для полной методологии и данных. Для получения дополнительной информации о cryptic peptides, изучите наши руководства по исследованию.

Цитирование

Ely Zackery A, Kulstad Zachary J, Gunaydin Gurcan et al.. (2025). Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition.. Science (New York, N.Y.). https://doi.org/10.1126/science.adk3487

Просмотр полного текста на PubMed

Связанные статьи

Исследуйте Дальнейшее

Это содержание основано на рецензированных исследованиях для образовательных целей только. Это не является медицинским советом. Всегда консультируйтесь с квалифицированным медицинским специалистом перед использованием каких-либо терапий на основе Peptide.